Effects of pravastatin on functional capacity in patients with chronic obstructive pulmonary disease and pulmonary hypertension

Tsung-Ming Lee, Chien Chang Chen, Hsiu Nien Shen, Nen Chung Chang

Research output: Contribution to journalArticle

73 Citations (Scopus)

Abstract

PH (pulmonary hypertension) often complicates the disease course of patients with COPD (chronic obstructive pulmonary disease) and is an indication of a worse prognosis. In the present study, we assessed whether pravastatin administration was effective in improving PH and exercise capacity in COPD patients with PH, and whether the pulmonary protection was mediated by inhibiting ET-1 (endothelin-1) production. In a double-blind parallel design, 53 COPD patients with PH were randomly assigned to receive either placebo or pravastatin (40 mg/day) over a period of 6 months at a medical centre. Baseline characteristics were similar in both groups. The exercise time remained stable throughout the study in the placebo group. After 6 months, the exercise time significantly increased 52% from 660±352 to 1006±316 s (P

Original languageEnglish
Pages (from-to)497-505
Number of pages9
JournalClinical Science
Volume116
Issue number6
DOIs
Publication statusPublished - Mar 2009

Keywords

  • Chronic obstructive pulmonary disease (COPD)
  • Dyspnoea
  • Endothelin-1 (ET-1)
  • Exercise capacity
  • Pulmonary hypertension
  • Statin

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'Effects of pravastatin on functional capacity in patients with chronic obstructive pulmonary disease and pulmonary hypertension'. Together they form a unique fingerprint.

  • Cite this